BACKGROUND: Although chemotherapy has improved outcome of osteosarcoma, 30-40% of patients succumb to this disease. Survivors experience substantial morbidity and mortality from anthracycline-induced cardiotoxicity. We hypothesized that the cardioprotectant dexrazoxane would (i) support escalation of the cumulative doxorubicin dose (600 mg/m(2)) and (ii) not interfere with the cytotoxicity of chemotherapy measured by necrosis grading in comparison to historical control data. PROCEDURE: Children and adolescents with nonmetastatic osteosarcoma were treated with MAP (methotrexate, doxorubicin, cisplatin) or MAPI (MAP/ifosfamide). Dexrazoxane was administered with all doxorubicin doses. Cardioprotection was assessed by measuring left ventricular fractional shortening. Interference with chemotherapy-induced cytotoxicity was determined by measuring tumor necrosis after induction chemotherapy. Feasibility of intensifying therapy with either high cumulative-dose doxorubicin or high-dose ifosfamide/etoposide was evaluated for "standard responders" (SR, <98% tumor necrosis at definitive surgery). RESULTS: Dexrazoxane did not compromise response to induction chemotherapy. With doxorubicin (450-600 mg/m(2)) and dexrazoxane, grade 1 or 2 left ventricular dysfunction occurred in five patients; 4/5 had transient effects. Left ventricular fractional shortening z-scores (FSZ) showed minimal reductions (0.0170 ± 0.009/week) over 78 weeks. Two patients (<1%) had secondary leukemia, one as a first event, a similar rate to what has been observed in prior trials. Intensification with high-dose ifosfamide/etoposide was also feasible. CONCLUSIONS: Dexrazoxane cardioprotection was safely administered. It did not impair tumor response or increase the risk of secondary malignancy. Dexrazoxane allowed for therapeutic intensification increasing the cumulative doxorubicin dose in SR to induction chemotherapy. These findings support the use of dexrazoxane in children and adolescents with osteosarcoma.
BACKGROUND: Although chemotherapy has improved outcome of osteosarcoma, 30-40% of patients succumb to this disease. Survivors experience substantial morbidity and mortality from anthracycline-induced cardiotoxicity. We hypothesized that the cardioprotectant dexrazoxane would (i) support escalation of the cumulative doxorubicin dose (600 mg/m(2)) and (ii) not interfere with the cytotoxicity of chemotherapy measured by necrosis grading in comparison to historical control data. PROCEDURE: Children and adolescents with nonmetastatic osteosarcoma were treated with MAP (methotrexate, doxorubicin, cisplatin) or MAPI (MAP/ifosfamide). Dexrazoxane was administered with all doxorubicin doses. Cardioprotection was assessed by measuring left ventricular fractional shortening. Interference with chemotherapy-induced cytotoxicity was determined by measuring tumor necrosis after induction chemotherapy. Feasibility of intensifying therapy with either high cumulative-dose doxorubicin or high-dose ifosfamide/etoposide was evaluated for "standard responders" (SR, <98% tumor necrosis at definitive surgery). RESULTS:Dexrazoxane did not compromise response to induction chemotherapy. With doxorubicin (450-600 mg/m(2)) and dexrazoxane, grade 1 or 2 left ventricular dysfunction occurred in five patients; 4/5 had transient effects. Left ventricular fractional shortening z-scores (FSZ) showed minimal reductions (0.0170 ± 0.009/week) over 78 weeks. Two patients (<1%) had secondary leukemia, one as a first event, a similar rate to what has been observed in prior trials. Intensification with high-dose ifosfamide/etoposide was also feasible. CONCLUSIONS:Dexrazoxane cardioprotection was safely administered. It did not impair tumor response or increase the risk of secondary malignancy. Dexrazoxane allowed for therapeutic intensification increasing the cumulative doxorubicin dose in SR to induction chemotherapy. These findings support the use of dexrazoxane in children and adolescents with osteosarcoma.
Authors: Allen M Goorin; Michael B Harris; Mark Bernstein; William Ferguson; Meenakshi Devidas; Gene P Siegal; Mark C Gebhardt; Cindy L Schwartz; Michael Link; Holcombe E Grier Journal: J Clin Oncol Date: 2002-01-15 Impact factor: 44.544
Authors: F Kung; F A Hayes; J Krischer; D Mahoney; B Leventhal; G Brodeur; D H Berry; R Dubowy; S Toledano Journal: Invest New Drugs Date: 1988-04 Impact factor: 3.850
Authors: J S Miser; T J Kinsella; T J Triche; M Tsokos; P Jarosinski; R Forquer; R Wesley; I Magrath Journal: J Clin Oncol Date: 1987-08 Impact factor: 44.544
Authors: A K Raymond; S P Chawla; C H Carrasco; A G Ayala; C V Fanning; B Grice; T Armen; C Plager; N E Papadopoulos; J Edeiken Journal: Semin Diagn Pathol Date: 1987-08 Impact factor: 3.464
Authors: Cameron K Tebbi; Wendy B London; Debra Friedman; Doojduen Villaluna; Pedro A De Alarcon; Louis S Constine; Nancy Price Mendenhall; Richard Sposto; Allen Chauvenet; Cindy L Schwartz Journal: J Clin Oncol Date: 2007-02-10 Impact factor: 44.544
Authors: Allen M Goorin; Douglas J Schwartzentruber; Meenakshi Devidas; Mark C Gebhardt; Alberto G Ayala; Michael B Harris; Lee J Helman; Holcombe E Grier; Michael P Link Journal: J Clin Oncol Date: 2003-04-15 Impact factor: 44.544
Authors: S S Legha; R S Benjamin; B Mackay; M Ewer; S Wallace; M Valdivieso; S L Rasmussen; G R Blumenschein; E J Freireich Journal: Ann Intern Med Date: 1982-02 Impact factor: 25.391
Authors: Přemysl Mladěnka; Lenka Applová; Jiří Patočka; Vera Marisa Costa; Fernando Remiao; Jana Pourová; Aleš Mladěnka; Jana Karlíčková; Luděk Jahodář; Marie Vopršalová; Kurt J Varner; Martin Štěrba Journal: Med Res Rev Date: 2018-01-05 Impact factor: 12.944
Authors: Fariba Navid; Victor M Santana; Michael Neel; M Beth McCarville; Barry L Shulkin; Jianrong Wu; Catherine A Billups; Shenghua Mao; Vinay M Daryani; Clinton F Stewart; Michelle Kunkel; Wendene Smith; Deborah Ward; Alberto S Pappo; Armita Bahrami; David M Loeb; Jennifer Reikes Willert; Bhaskar N Rao; Najat C Daw Journal: Int J Cancer Date: 2017-07-03 Impact factor: 7.396
Authors: Kelly D Getz; Lillian Sung; Todd A Alonzo; Kasey J Leger; Robert B Gerbing; Jessica A Pollard; Todd Cooper; E Anders Kolb; Alan S Gamis; Bonnie Ky; Richard Aplenc Journal: J Clin Oncol Date: 2020-04-28 Impact factor: 44.544
Authors: Neyssa M Marina; Qi Liu; Sarah S Donaldson; Charles A Sklar; Gregory T Armstrong; Kevin C Oeffinger; Wendy M Leisenring; Jill P Ginsberg; Tara O Henderson; Joseph P Neglia; Marilyn A Stovall; Yutaka Yasui; R Lor Randall; David S Geller; Leslie L Robison; Kirsten K Ness Journal: Cancer Date: 2017-02-21 Impact factor: 6.860
Authors: Sara Vandenwijngaert; Melissa Swinnen; Ann-Sophie Walravens; Manu Beerens; Hilde Gillijns; Ellen Caluwé; Robert E Tainsh; Daniel I Nathan; Kaitlin Allen; Peter Brouckaert; Jozef Bartunek; Marielle Scherrer-Crosbie; Kenneth D Bloch; Donald B Bloch; Stefan P Janssens; Emmanuel S Buys Journal: Antioxid Redox Signal Date: 2016-09-08 Impact factor: 8.401